Monte Rosa stock price rises due to prostate cancer trial results

LootboxPhobia · 2026-02-25T00:53:59+00:00

Monte Rosa Therapeutics announced its Phase 1/2 clinical data of MRT-2359 combined with enzalutamide for metastatic castration-resistant prostate cancer, with PSA response rate and disease control rate both at 100% among patients. The overall RECIST disease control rate was 67%, and the treatment was well tolerated. The company plans to initiate Phase 2 studies in 2026.

LootboxPhobia

2026-02-25 00:53:59

Abstract generation in progress

Investing.com – Monte Rosa Therapeutics Inc (NASDAQ:GLUE) stock rose 3.9% in pre-market trading on Tuesday after the company announced positive clinical data from a Phase 1/2 study of MRT-2359 combined with enzalutamide for metastatic castration-resistant prostate cancer.

The company reported that in patients with metastatic castration-resistant prostate cancer with androgen receptor mutations, MRT-2359 combined with enzalutamide achieved a 100% PSA response rate and a 100% disease control rate in five patients. Among these, two patients achieved RECIST partial responses, three patients had stable disease, and all target lesions shrank.

Among all 15 evaluable patients, the overall RECIST disease control rate was 67%, with 10 out of 15 showing tumor volume reduction in target lesions. This patient population had previously received extensive treatments, with 78% having been treated with second-generation androgen receptor inhibitors and 83% having received taxane chemotherapy.

The combination therapy was generally well tolerated, with most adverse events being Grade 1-2, including fatigue, diarrhea, nausea, and decreased appetite. No patients discontinued treatment due to adverse events.

The data was presented on Wednesday at the 2026 ASCO GU Symposium in San Francisco. Monte Rosa plans to initiate a Phase 2 study of MRT-2359 combined with a second-generation androgen receptor inhibitor in the third quarter of 2026. The study will use a two-stage design, recruiting up to 25 patients with metastatic castration-resistant prostate cancer harboring androgen receptor mutations.

MRT-2359 is an investigational oral bioavailable molecular degrader targeting GSPT1. The drug works by selectively degrading the translation termination factor GSPT1, disrupting the translation process, which MYC-driven cancers rely on for rapid growth.

This article was translated with artificial intelligence assistance. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.